Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Peficitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 known ✓ | P52333 | 18/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 17/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 16/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Peficitinib SCHEMBL16199899 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL16199902 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL1155034 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL1154418 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL17645135 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL24212690 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL9990248 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL1154421 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL22404910 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL4447032 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408835-B2 | Pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2016-08-09 | — | — | US | claimed |
| EP-2592080-B1 | CRYSTAL OF FUSED PYRIDINE COMPOUND SALT | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | claimed |
| US-20160045479-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA INC. (JP) | 2016-02-18 | — | — | US | claimed |
| EP-2979698-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Astellas Pharma Inc. (JP) | 2016-02-03 | — | — | EP | claimed |
| US-9408835-B2 | Pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9408835-B2 | Pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2016-08-09 | — | — | US | disclosed |
| EP-2592080-B1 | CRYSTAL OF FUSED PYRIDINE COMPOUND SALT | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20160045479-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA INC. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160045479-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA INC. (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2979698-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Astellas Pharma Inc. (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2979698-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Astellas Pharma Inc. (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-8779140-B2 | Crystal of fused pyridine compound salt | ASTELLAS PHARMA INC. (JP) | 2014-07-15 | — | — | US | disclosed |
| WO-2013147135-A1 | CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION | アステラス製薬株式会社 (JP) | 2013-10-03 | — | — | WO | disclosed |
| EP-2592080-A1 | CRYSTAL OF FUSED PYRIDINE COMPOUND SALT | Astellas Pharma Inc. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130102628-A1 | CRYSTAL OF FUSED PYRIDINE COMPOUND SALT | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| WO-2011162300-A1 | CRYSTAL OF FUSED PYRIDINE COMPOUND SALT | アステラス製薬株式会社 (JP) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045479-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | PGA5, TAS2R5, TAS2R7 | JAK3 655/4885JAK2 2637/4885JAK1 260/4885 |
| US-20130102628-A1 | CRYSTAL OF FUSED PYRIDINE COMPOUND SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, SDHB | JAK3 1123/4885JAK2 638/4885JAK1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.